Clinical trials: Oral Anticoagulant
Venipuncture Site Bruise
Blood Sample Collection in Geriatric Patients
This study aimed to evaluate the effect of different durations of a specific pressure applied after blood collection on the development of ecchymosis in geriatric patients using oral and subcutaneous anticoagulants.
- Trial name
- NCT05580965
- Testing
- 20 N pressure for 1 minute, 20 N pressure for 3 minute, 20 N pressure for 5 minute
- Where
- Turkey (Türkiye)
- Volunteers
- 164 people
- Sponsor
- Saglik Bilimleri Universitesi
Anticoagulants, Self Efficacy
Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
This study aims to develop and validate an index measurement tool to assess the patient's self-care self-efficacy in managing oral anticoagulation therapy (OAC).
- Conditions
- Anticoagulants, Self Efficacy, Self Confidence
- Trial name
- SCSE-OAC (NCT05820854)
- Testing
- Self-assess and reporting self-care self-efficacy levels
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
OAC-ICH, Acute Management of OAC-ICH
geRman-widE mulTicenter Analysis of oRal Anticoagulation-associated intraCerebral hEmorrhage
Intracerebral hemorrhage [ICH] is the most feared complication of anticoagulant therapy [OAC]. Evidence regarding acute therapeutic interventions as well as secondary treatment approaches is still limited.
- Conditions
- OAC-ICH, Acute Management of OAC-ICH, Resumption of OAC
- Trial name
- RETRACE (NCT01829581)
- Testing
- no intervention, only descriptive data analysis
- Volunteers
- 1,205 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Atrial Fibrillation
Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the…
- Trial name
- TREND (NCT03474757)
- Testing
- Data Collection
- Where
- Colombia
- Volunteers
- 10,528 people
- Sponsor
- Bayer
Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs)
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of…
- Conditions
- Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs), Thrombotic and Bleeding Events, Safety
- Trial name
- OBSTINATE 2 (NCT06929182)
- Testing
- "non-high risk" thrombotic APS patients treated with DOAC
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Per-procedural Concentrations of Oral Anticoagulants
Per-procedural Concentration of Direct Oral Anticoagulants
Background: Peri-procedural management of direct oral anticoagulants (DOAC) is challenging. The optimal duration of pre-procedural discontinuation that guarantees a minimal DOAC concentration ([DOAC]) at surgery is unknown.
- Trial name
- CORIDA (NCT02643992)
- Testing
- DOAC concentration measurement
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Atrial Fibrillation, Heart Failure
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
Observational study of elderly individuals diagnosed with Non-Valvular Atrial Fibrillation and Heart Failure who are beginning oral blood thinners
- Trial name
- NCT03508271
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 60,000 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Atrial Fibrillation
Validation of Predictors of OAC Initiation Using EMR Data
The objectives of this study are, first, to identify select clinical covariates from electronic medical records (EMR) that might be associated with initiation of oral anticoagulant medications (dabigatran or warfarin) in patients…
- Trial name
- NCT03006341
- Testing
- Dabigatran etexilate, Warfarin
- Where
- United States
- Volunteers
- 140,187 people
- Sponsor
- Boehringer Ingelheim
Traumatic Intracranial Haemorrhage
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
Older people falling from a standing height is the most common cause of hospital admission for head injury. Up to 1 in 3 patients admitted are taking a tablet medication which thins the blood, known as an oral anticoagulant.
- Trial name
- RESTARTtlCrH (NCT06322953)
- Testing
- Direct-Acting Oral Anticoagulants (used as per local standard practice)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,084 people
- Sponsor
- Walton Centre NHS Foundation Trust
Venous Thromboembolism
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal…
- Trial name
- NCT01857583
- Testing
- 15mg DU-176b, 30mg DU-176b, Fondaparinux
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Cardiovascular Complications, Hemorrhagic Disorders
Comparison of Accidents and Their Circumstances With Oral Anticoagulants
Differences in efficacy and safety between new oral anticoagulants (NOAC) and vitamin K antagonist (VKA) in real practice remain uncertain.
- Conditions
- Cardiovascular Complications, Hemorrhagic Disorders, Embolism and Thrombosis
- Trial name
- CACAO (NCT02376777)
- Testing
- Follow up
- Where
- 33 sites in France
- Volunteers
- 4,162 people
- Sponsor
- CNGE IRMG Association
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Influenza
Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy
Until now, the best administration route of the anti-flu vaccine for patients receiving long term oral anticoagulation therapy has been the subcutaneous one; the intramuscular route has not been recommended because it may…
- Trial name
- NCT00137579
- Testing
- Influenza vaccine intramuscular administration route
- Where
- 4 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Catalan Institute of Health
Atrial Fibrillation
The Effectiveness of Interactive Nursing Education Program Through Health Belief Model Based and Informative Technology-assisted on Atrial Fibrillation Patients Receiving Oral Anticoagulant
This study examined patients on taking oral anticoagulants (OACs) are often prescribed for Atrial fibrillation (AFib) to determine the effectiveness of a multiple interactive health education program, which was developed based on…
- Trial name
- NCT05145634
- Testing
- Patient education related oral anticoagulants (OACs)
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital
Angina, Stable, Angina, Unstable
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher…
- Conditions
- Angina, Stable, Angina, Unstable, Anticoagulants
- Trial name
- COBRA-REDUCE (NCT02594501)
- Testing
- COBRA PzF, Drug Eluting Stent
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 996 people
- Sponsor
- CeloNova BioSciences, Inc.
Intracerebral Hemorrhage
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixaban and rivaroxaban.
- Trial name
- TICH-NOAC (NCT02866838)
- Testing
- Tranexamic acid, Saline 0.9%
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- University Hospital, Basel, Switzerland
Venous Thromboembolism
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
- Trial name
- EPICT (NCT04066764)
- Testing
- Rivaroxaban, Warfarin, Nadroparin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine